Вестник трансплантологии и искусственных органов

Расширенный поиск


Полный текст:


Об авторах

А. И. Сушков
ФГБУ «Федеральный научный центр трансплантологии и искусственных органов им. академика В.И. Шумакова» Минздрава РФ, г. Москва

Я. Г. Мойсюк
ФГБУ «Федеральный научный центр трансплантологии и искусственных органов им. академика В.И. Шумакова» Минздрава РФ, г. Москва ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова», кафедра трансплантологии и искусственных органов

Список литературы

1. Мойсюк Я.Г. и соавт. Иммуносупрессия при транс- плантации почки // Иммуносупрессия при транс- плантации солидных органов / Под ред. С.В. Готье. М.: Триада, 2011. С. 46–113.

2. Abrams J.R. et al. Blockade of T lymphocyte costimu- lation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pa- thology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells // J. Exp. Med. 2000. Vol. 192 (5). P. 681–694.

3. Adams A.B. et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival // J. Immunol. 2005. Vol. 174 (1). P. 542–550.

4. Cardona K. et al. Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways // Nat. Med. 2006. Vol. 12 (3). P. 304–306.

5. Davis P.M., Nadler S. and Suchard S.J. Belatacept does not mediate complement-dependent cytotoxicity or an- tibody-dependent cellular cytotoxicity // Am. J. Trans- plant. 2008. Vol. 8.

6. Durrbach A., Grinyo J. and Vanrenterghem Y. Bela- tacept compared with cyclosporine in renal allograft recipients of extended criteria donor kidneys: 3-year outcomes from the phase III BENEFIT-EXT trial, in Annual Congress ERA EDTA. 2011: Prague, Czech Republic.

7. Durrbach A. et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended crite- ria donors (BENEFIT-EXT study) // Am. J. Transplant. 2010. Vol. 10 (3). P. 547–557.

8. Emamaullee J.A. et al. Belatacept and basiliximab di- minish human antiporcine xenoreactivity and synergize to inhibit alloimmunity // Transplantation. 2008. Vol. 85 (1). P. 118–124.

9. Ferguson R. et al. Immunosuppression with belatacept- based, corticosteroid-avoiding regimens in de novo kidney transplant recipients // Am. J. Transplant. 2011. Vol. 11 (1). P. 66–76.

10. Fife B.T., Bluestone J.A. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways // Immunol. Rev. 2008. Vol. 224. P. 166–182.

11. Gaston R.S. Chronic calcineurin inhibitor nephrotoxici- ty: reflections on an evolving paradigm // Clin. J. Am. Soc. Nephrol. 2009. Vol. 4 (12). P. 2029–2034.

12. Grinyo J. et al. An integrated safety profile analysis of belatacept in kidney transplant recipients // Transplanta- tion. 2010. Vol. 90 (12). P. 1521–1527.

13. Hess R.D. Routine Epstein–Barr virus diagnostics from the laboratory perspective: still challenging after 35 ye- ars // J. Clin. Microbiol. 2004. Vol. 42 (8). P. 3381–3387.

14. Kirk A.D. et al. Induction therapy with monoclonal anti- bodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates // Transplantation, 2001. Vol. 72 (3). P. 377–384.

15. Kremer J.M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion pro- tein CTLA4Ig // N. Engl. J. Med. 2003. Vol. 349 (20). P. 1907–1915.

16. Larsen C.P. et al. Rational development of LEA29Y (be- latacept), a high-affinity variant of CTLA4-Ig with po- tent immunosuppressive properties // Am. J. Transplant. 2005. Vol. 5 (3). P. 443–453.

17. Latek R. et al. Assessment of belatacept-mediated co- stimulation blockade through evaluation of CD80/86- receptor saturation // Transplantation. 2009. Vol. 87 (6). P. 926–933.

18. Levisetti M.G. et al. Immunosuppressive effects of hu- man CTLA4Ig in a non-human primate model of allo- geneic pancreatic islet transplantation // J. Immunol. 1997. Vol. 159 (11). P. 5187–5191.

19. Li X.C., Rothstein D.M., Sayegh M.H. Costimulatory pa- thways in transplantation: challenges and new develop- ments // Immunol. Rev. 2009. Vol. 229 (1). P. 271–293.

20. Linsley P.S. et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors // Immunity. 1994. Vol. 1 (9). P. 793–801.

21. Linsley P.S. et al. Immunosuppression in vivo by a so- luble form of the CTLA-4 T cell activation molecule // Science. 1992. Vol. 257 (5071). P. 792–795.

22. Meier-Kriesche H.U., Schold J.D., Kaplan B. Long- term renal allograft survival: have we made significant progress or is it time to rethink our analytic and thera- peutic strategies? // Am. J. Transplant. 2004. Vol. 4 (8). P. 1289–1295.

23. Nankivell B.J. et al. The natural history of chronic al- lograft nephropathy // N. Engl. J. Med. 2003. Vol. 349 (24). P. 2326–2333.

24. Rangel E.B. Belatacept in clinical and experimental transplantation – progress and promise // Drugs Today (Barc). 2010. Vol. 46 (4). P. 235–242.

25. Sakaguchi S. et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and trans- plantation tolerance // Immunol. Rev. 2001. Vol. 182. P. 18–32.

26. Tang, Q. et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells // J. Im- munol. 2003. Vol. 171 (7). P. 3348–3352.

27. Vanrenterghem Y. et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies) // Transplantation. 2011. Vol. 91 (9). P. 976–983.

28. Vierboom M.P. et al. Induction of allograft tolerance through costimulatory blockade: first selection of drugs in vitro // Transpl. Immunol. 2003. Vol. 11 (2). P. 215– 222.

29. Vincenti F. et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in

30. renal transplant recipients (BENEFIT study) // Am. J.

31. Transplant. 2010. Vol. 10 (3). P. 535–546.

32. Vincenti F., Larsen C., Alberu J. Three-year outcomes from benefit: a phase III study of belatacept vs. cyclospo- rine in kidney transplant recipients., in Annual Congress

33. ERA EDTA. 2011: Prague, Czech Republic.

34. Vincenti F. et al. Costimulation blockade with belatacept in renal transplantation // N. Engl. J. Med. 2005. Vol. 353

35. (8). P. 770–781.


Для цитирования:

Сушков А.И., Мойсюк Я.Г. БЕЛАТАЦЕПТ ПРИ ТРАНСПЛАНТАЦИИ ПОЧКИ. Вестник трансплантологии и искусственных органов. 2013;15(1):96-105.

For citation:

Sushkov A.I., Moysyuk Y.G. BELATACEPT IN RENAL TRANSPLANTATION. Russian Journal of Transplantology and Artificial Organs. 2013;15(1):96-105. (In Russ.)

Просмотров: 1145

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1995-1191 (Print)
ISSN 2412-6160 (Online)